bempedoic acid sold brand name nexletol among others medication treatment hypercholesterolemia high blood cholesterol common side effects include hyperuricemia high blood levels uric acid pain arms legs anemia low red blood cell bempedoic acid blocks enzyme liver called adenosine triphosphatecitrate lyase involved making bempedoic acid approved use united states february use european union april us food drug administration fda considers firstinclass us bempedoic acid indicated treatment hypercholesterolemia combination diet highest tolerated statin therapy adults heterozygous familial hypercholesterolemia established atherosclerotic cardiovascular disease need additional lowering ldl eu bempedoic acid indicated adults primary hypercholesterolaemia heterozygous familial non familial mixed dyslipidaemia adjunct diet combination statin statin lipidlowering therapies patients unable reach ldlc goals maximum tolerated dose statin alone combination lipidlowering therapies patients statin statin common adverse effects clinical trials muscle spasms treated patients compared placebo pain back versus limb versus gout versus gastrointestinal problems diarrhea less common serious adverse effect tendon rupture rotator cuff shoulder biceps tendon achilles tendon versus bempedoic acid interact cytochrome enzyme system liver weakly inhibits transporter proteins latter possibly responsible increase uric acid blood therefore adverse effect gout despite drug increases blood levels statins effect pronounced simvastatin pravastatin whose auc increased twofold clinically relevant interactions found bempedoic acid prodrug activated thioester coenzyme enzyme activated substance inhibits atp citrate lyase involved livers biosynthesis cholesterol upstream hmgcoa reductase enzyme blocked substance also activates ampactivated protein kinase effect likely relevant following oral intake bempedoic acid reaches highest blood plasma concentrations food affect bloodstream substance bound plasma fifth substance reversibly converted aldoketo reductase enzyme metabolite called also pharmacologically active form coenzyme bound plasma bempedoic acid metabolite inactivated glucuronidation carboxylic acid bempedoic acid biological halflife substance excreted form metabolites urine two clinical trials evaluated benefits side effects bempedoic trial designs enrolled subjects lipidlowering diet taking highest dose statin drug commonly used lower cholesterol high trials subjects randomly assigned receive bempedoic acid placebo tablets every day neither subjects health care providers knew treatment trials measured percent change ldl cholesterol ldlc blood levels baseline week twelve compared bempedoic acid one clinical trial bempedoic acid reduced ldlc mgdl compared placebo similar frequency side effects placebo although higher percentage drugreceiving subjects dropped study side effects vs one randomized controlled trial patients could tolerate therapy statins reduced risk major adverse cardiovascular events treated bempedoic january committee medicinal products human use chmp european union recommended granting marketing authorization bempedoic acid standalone drug brand name fixeddose combination medication ezetimibe brand name bempedoic acid approved use european union april combination bempedoic acidezetimibe approved march february bempedoic acid approved use united states standalone drug brand name fixeddose combination ezetimibe brand name us food drug administration fda granted approval nexletol esperion fda approved bempedoic acid based evidence two clinical trials trial trial subjects high ldl cholesterol known atherosclerotic cardiovascular disease trials conducted united states canada httpsenwikipediaorgwikibempedoicacid